Semma Therapeutics, a Cambridge, Massachusetts-based biopharmaceutical company, raised an undisclosed amount of funding.
JDRF T1D Fund, a venture philanthropy fund devoted to finding and funding the best early-stage T1D commercial opportunities, made the investment.
Founded in 2014 by Robert Millman, CEO, Semma Therapeutics is a biopharmaceutical company developing Stem Cell-derived Islet therapy for type 1 diabetes (T1D) patients who currently depend on insulin injections.
Ongoing research at Semma is focused on combining proprietary Stem Cell-derived Islet cells, or “SC-Islets,” with a cell delivery and immune protection strategy that can protect these cells from the patient’s immune system and allow the beta cells to function as they do in non-diabetic individuals.
The company is backed by MPM Capital, F-Prime Capital, and strategic investors Novartis and Medtronic.